News

Garth T. Whiteside, PhD, head of preclinical development at Imbrium Therapeutics, discussed a phase 2 clinical study that explored the use of sunobinop in patients with insomnia during recovery from alcohol use disorder.

CHALLENGE-MIG, a 3-month study, is the first trial to compare the efficacy of 2 previously approved calcitonin gene-related peptide antagonists in the treatment of migraine.

Biomarker data at 49 weeks continued to demonstrate that DNL310 enabled rapid and sustained normalization of CSF heparan sulfate to normal healthy levels and improvement in lysosomal function biomarkers.

Over a 12-week period, PTC518 showed a safe and tolerable profile, with significant reductions in mutant huntingtin protein and an overall trend towards lowering of neurofilament light levels.

Following the initiation or switch to a new migraine preventive medication, patients taking galcanezumab showed numerically greater 3-month improvements for most measures of health-related quality of life and disability.

The associate professor of neurology at Mayo Clinic discussed the developing field of migraine management during pregnancy and the importance of raising awareness of treatment options during the gestation period. [WATCH TIME: 4 minutes]

At the 2023 AHS Annual Meeting, the chief of headache at UT Austin Dell Children’s Hospital discussed her presentation on a new educational intervention to improve knowledge of pediatric headache.

The basis for the FDA’s decision came from the phase 3 ADAPT-SC study, in which subcutaneous efgartigimod showed a slightly better ability to reduce immunoglobulin compared with its previously approved intravenous formulation.

The combination of both REN and gepants for acute migraine treatment may have an increased efficacy compared with REN alone, an expected result based on the different actions of the treatments.

The director of the Pediatric Headache Program at the Children’s Hospital of Philadelphia talked about the usage of an integrated EHR questionnaire to improve the likelihood of specific diagnosis in pediatric headache. [WATCH TIME: 5 minutes]

Walter Koroshetz, MD, director of the National Institutes of Neurological Disorders and Stroke at the NIH, provided perspective on the advances in migraine treatment, and the next steps in research needed over the coming years.

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine provided perspective on how cannabis may be used in the management of migraine as more evidence is uncovered. [WATCH TIME: 3 minutes]

Data showed similar rates of discontinuation because of adverse events between those with and without CGRP monoclonal antibodies, as well as no serious AEs observed for those on concomitant medication.

The postdoctoral researcher at Harvard Medical School discussed the relationship between sensory neurons and the neuropeptide CGRP in regulating gut immunity. [WATCH TIME: 6 minutes]

The use of intravenous ketamine in pediatric patients with refractory headaches resulted in a median pain reduction of 50% at discharge and nearly two-third of patients did not need further rescue therapies 1 month posttreatment.

The associate professor at Yeshiva University and Albert Einstein College of Medicine discussed the significance of recognizing the behavioral aspects of migraine management such as lifestyle choices, medical interventions, and societal influences. [WATCH TIME: 4 minutes]

Here's some of what is coming soon to NeurologyLive® this week.

The headache specialist at the Hartford Healthcare Headache Center discussed a study that explored changes in the vasculature and retinal blood perfusion of the eye during migraine attacks. [WATCH TIME: 5 minutes]

Compared with the overall population, outcomes for the coprimary end points of pain freedom and freedom from most bothersome symptom at 2 hours postdose remained superior in rimegepant-treated individuals.

The director of the Neuroinformatics Program at the University of California, Irvine, provided insight on the use of self-organizing maps to cluster different groups of patients with migraine. [WATCH TIME: 4 minutes]

Atogepant 60 mg once daily group had significantly larger reductions in mean monthly migraine days across weeks 1-12 and weeks 9-12, with no statistical difference in treatment-emergent adverse events or all-cause discontinuation.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of the American Headache Society.

The pain management specialist and headache neurologist at the University of California San Diego Center for Pain Medicine discussed promising findings from a placebo-controlled trial assessing cannabis in patients with migraine. [WATCH TIME: 5 minutes]

Elizabeth K. Seng, PhD, associate professor at Yeshiva University and Albert Einstein College of Medicine, talked about migraine management through the lens of behavioral factors that clinicians can recommend and encourage to their patients.

The associate professor of psychiatry at the University of Illinois at Chicago discussed the various working groups that have been formed to determine the priorities for different topics in migraine at the 2023 AHS Annual Meeting. [WATCH TIME: 5 minutes]

Allison Verhaak, PhD, a clinical psychologist from Ayer Neuroscience Institute at Hartford Healthcare Headache Center, discussed focus group and survey data on themes in migraine-related stigma, and the importance of creating a migraine specific stigma scale.

Neurology News Network for the week ending June 17, 2023. [WATCH TIME: 3 minutes]

A retrospective cohort study observed no significant difference in the number of patients who discontinued concurrent peripheral nerve blocks and onabotulinumtoxinA, which the authors recognized as a marker of clinical relevance.